Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

218,311-218,340 of 319,975

filter-aware
32
The slide highlights both regulatory NCE exclusivity and a specific count of issued/pending patents.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
33
Includes a logo grid at the bottom representing past affiliations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
34
Includes details on options, warrants, and insider ownership percentage.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
35
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
36
The chart compares the $42B combined market of major CPIs against a $0.5B figure, likely representing the company's specific asset or segment.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
37
The slide uses a logo-grid and metric-grid to establish valuation context.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
38
The slide uses a growth curve background to imply value accumulation over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Slide 1
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
03
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
04
The slide uses hub-and-spoke diagrams to visually contrast decentralized vs centralized networks.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
The slide presents clinical validation data for the ColoAlert diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Traction1 hit
10
The slide features a minimalist design with a corporate logo and a halftone dot pattern.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the disease progression.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
AA = Advanced Adenoma; CRC = Colorectal Cancer. Data sourced from JNCI 2022.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide uses a process flow to demonstrate the technical workflow of the diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
14
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
16
The slide outlines a multi-step diagnostic process involving FIT analysis and proprietary DNA/mRNA extraction.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
17
The slide provides clinical trial data breakdown for a diagnostic product.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
Includes a highlighted box emphasizing the primary performance metrics for CRC and AA detection.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
The slide uses two scatter plots to compare diagnostic performance metrics against competitors like Guardant Health, Cologuard, and CellMax Life.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market SizeLoop · Mece Breakdown1 hit
20
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Mece Breakdown1 hit
21
Includes a footer note about future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
22
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit